Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men

Japanese Men ◽

Dipeptidyl Peptidase 4 ◽

Multiple Dose Pharmacokinetics

First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Clinical Drug Investigation ◽

10.1007/s40261-021-01088-5 ◽

2021 ◽

Author(s):

Lu Wang ◽

Jinmiao Lu ◽

Sufeng Zhou ◽

Yuqing Zhao ◽

Lijun Xie ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Food Effect ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229)

Diabetes Obesity and Metabolism ◽

10.1111/dom.12813 ◽

2016 ◽

Vol 19 (2) ◽

pp. 294-298 ◽

Cited By ~ 10

Author(s):

Jaeseong Oh ◽

Andrew HyoungJin Kim ◽

SeungHwan Lee ◽

Hyunjeong Cho ◽

Yon Su Kim ◽

...

Keyword(s):

Renal Impairment ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor

Clinical Pharmacokinetics ◽

10.1007/s40262-016-0421-4 ◽

2016 ◽

Vol 56 (1) ◽

pp. 11-24 ◽

Cited By ~ 12

Author(s):

David W. Boulton

Keyword(s):

Dipeptidyl Peptidase ◽

Clinical Pharmacokinetics ◽

Dipeptidyl Peptidase 4 ◽

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects

British Journal of Clinical Pharmacology ◽

10.1111/j.1365-2125.2011.03937.x ◽

2011 ◽

Vol 72 (1) ◽

pp. 92-102 ◽

Cited By ~ 18

Author(s):

Vijay V. Upreti ◽

David W. Boulton ◽

Li Li ◽

Agatha Ching ◽

Hong Su ◽

...

Keyword(s):

Healthy Subjects ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase‐4 Inhibitor: A Randomized, Double‐Blinded, Placebo‐Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus

Clinical Pharmacology in Drug Development ◽

10.1002/cpdd.895 ◽

2021 ◽

Author(s):

Min Wu ◽

Qian‐Qian Li ◽

Hong Zhang ◽

Xiao‐Xue Zhu ◽

Xiao‐Jiao Li ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Dipeptidyl Peptidase ◽

Daily Administration ◽

Dipeptidyl Peptidase 4 ◽

Double Blinded

Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects

Clinical Pharmacokinetics ◽

10.2165/11536620-000000000-00000 ◽

2010 ◽

Vol 49 (12) ◽

pp. 829-840 ◽

Cited By ~ 34

Author(s):

Silke Retlich ◽

Vincent Duval ◽

Arne Ring ◽

Alexander Staab ◽

Silke Hüttner ◽

...

Keyword(s):

Dipeptidyl Peptidase ◽

Absolute Bioavailability ◽

Healthy Male ◽

Dipeptidyl Peptidase 4 ◽

Male Subjects

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

Clinical Therapeutics ◽

10.1016/j.clinthera.2008.03.004 ◽

2008 ◽

Vol 30 (3) ◽

pp. 499-512 ◽

Cited By ~ 90

Author(s):

P COVINGTON ◽

R CHRISTOPHER ◽

M DAVENPORT ◽

P FLECK ◽

Q MEKKI ◽

...

Keyword(s):

Type 2 Diabetes ◽

Multiple Dose ◽

Dipeptidyl Peptidase ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Multiple Dose Study ◽

Dose Study

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

Drug Design Development and Therapy ◽

10.2147/dddt.s65678 ◽

2014 ◽

pp. 1709 ◽

Cited By ~ 21

Author(s):

Namyi Gu ◽

Min Kyu Park ◽

Tae-Eun Kim ◽

Mi Young Bahng ◽

Sang-Heon Cho ◽

...

Keyword(s):

Healthy Volunteers ◽

Multiple Dose ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase Iv ◽

Multiple Dose Pharmacokinetics

P201 - Safety, pharmacokinetics and pharmacodynamics effects of multiple-dose administration of fotagliptin benzoate-dipeptidyl peptidase-4 inhibitor in type 2 diabetes mellitus

Drug Metabolism and Pharmacokinetics ◽

10.1016/j.dmpk.2020.04.202 ◽

2020 ◽

Vol 35 (1) ◽

pp. S83

Author(s):

Min Wu ◽

Ji Chen ◽

Haigang Sun ◽

Hong Zhang ◽

Xiaojiao Li ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Multiple Dose ◽

Dose Administration ◽

Dipeptidyl Peptidase 4 ◽

Multiple Dose Administration ◽

Pharmacokinetic and Pharmacodynamic Assessments of the Dipeptidyl Peptidase-4 Inhibitor PHX1149: Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Studies in Healthy Subjects

Clinical Therapeutics ◽

10.1016/j.clinthera.2007.08.005 ◽

2007 ◽

Vol 29 (8) ◽

pp. 1692-1705 ◽

Cited By ~ 22

Author(s):

A. Marie O'Farrell ◽

Andre van Vliet ◽

Khalid Abou Farha ◽

Julie M. Cherrington ◽

David A. Campbell ◽

...

Keyword(s):

Healthy Subjects ◽

Multiple Dose ◽

Dipeptidyl Peptidase ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽